Last reviewed · How we verify
NCT05422547
Role of Immunoscore® in Stage II-III Colorectal Cancer
trial testing Immunoscore Colon Test in Colon Adenocarcinoma in 100 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | D'Or Institute for Research and Education |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 April 2022 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 December 2023 |
| Sites | 2 locations across Brazil |
Drugs / interventions tested
- Immunoscore Colon Test
Conditions studied
- Colon Adenocarcinoma — all drugs for Colon Adenocarcinoma →
Sponsor
D'Or Institute for Research and Education
Who can join
Eligibility, any sex, with Colon Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study is a bidirectional analytical study, composed of a retrospective and a prospective cohorts. Patients with stage II - III colorectal cancer undergoing oncological surgery will be analyzed. The study will include a convenience sample of 100 individuals. Fifty cases will be included retrospectively and fifty prospectively. The study aims to evaluate the benefit of using the Immunoscore test as a predictor of recurrence in patients with operated stage II-III colon tumors. It will also be evaluated the impact on oncologic decision and costs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05422547
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colon Adenocarcinoma
Currently open trials in the same condition.
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108 · Phase 3 · recruiting
- NCT06652672 — Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma · NA · recruiting
- NCT06709885 — HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer · Phase 2 · recruiting
- NCT06640166 — Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Co · Phase 2 · recruiting
Other D'Or Institute for Research and Education trials
Trials by the same sponsor.
- NCT07372144 — Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment · Phase 3 · not yet recruiting
- NCT07074106 — TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC · Phase 2 · recruiting
- NCT06725537 — Comprehensive Demographics and Clinical Profile of NSCLC Patients · not yet recruiting
- NCT06002841 — Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure · Phase 1, PHASE2 · unknown
- NCT06091384 — Inspiratory Muscle Strength Training in Post-Covid Syndrome · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05422547 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by D'Or Institute for Research and Education
- Last refreshed: 16 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05422547.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing